natgillin/translations-raw huggingface dataset:
Aerivio Spiromax should only be used to treat severe asthma in adults aged 18 years and older and adults with COPD.
Aerivio Spiromax smije se primjenjivati samo za liječenje teške astme u odraslih u dobi od 18 godina i starijih te odraslih s KOPB-om.
Aerivio Spiromax should only be used to treat severe asthma in adults aged 18 years and older and adults with COPD.
Airexar Spiromax smije se primjenjivati samo za liječenje teške astme u odraslih u dobi od 18 godina i starijih te odraslih s KOPB-om.
Aerobic Gram- negative bacteria Haemophilus influenzae$* Haemophilus parainfluenzae$ Legionella pneumophila Moraxella catarrhalis*
Aerobne gram-negativne bakterije Haemophilus influenzae$* Haemophilus parainfluenzae$ Legionella pneumophila Moraxella catarrhalis
Aerobic Gram-positive bacteria
Aerobne gram-pozitivne bakterije
Aesica Pharmaceuticals GmbH, Alfred-Nobel Strasse 10, D-40789 Monheim am Rhein, Germany .
Aesica Pharmaceuticals GmbH, Alfred-Nobel Strasse 10, D-40789 Monheim am Rhein, Njemačka .
Aesica Queenborough Limited Queenborough
Aesica Queenborough Limited Queenborough Kent ME11
Aesica Queenborough Limited, North Road, Queenborough, Kent, ME11 5EL, United Kingdom
Aesica Queenborough Limited, North Road, Queenborough, Kent, ME11 5EL, Ujedinjeno Kraljevstvo
Aesica Queenborough Limited, Queenborough, Kent ME11 5EL, United Kingdom AbbVie Logistics B.V., Zuiderzeelaan 53, 8017 JV Zwolle, The Netherlands
Aesica Queenborough Limited, Queenborough, Kent ME11 5EL, Ujedinjeno Kraljevstvo AbbVie Logistics B.V., Zuiderzeelaan 53, 8017 JV Zwolle, Nizozemska
AESIs will be defined as follows:
Ti se događaji definiraju na sljedeći način:
Afamelanotide is a synthetic tridecapeptide and a structural analogue of α-melanocyte stimulating hormone (α-MSH).
Afamelanotid je sintetski tridekapeptid i strukturalni analog α-melanocit stimulirajućeg hormona (α-MSH).
Afamelanotide is thought to mimic the endogenous compound’s pharmacological activity by activating the synthesis of eumelanin mediated by the MC1R receptor.
Smatra se da afamelanotid oponaša farmakološko djelovanje endogenog spoja aktivirajući sintezu eumelanina putem receptora MC1R.
Afatinib 20 mg, single dose
Afatinib 20 mg, jednokratna doza
Afatinib retains significant anti-tumour activity in NSCLC cell lines in vitro and/or tumour models in vivo (xenografts or transgenic models) driven by mutant EGFR isoforms known to be resistant to the reversible EGFR inhibitors erlotinib and gefitinib such as T790M or T854A.
Afatinib zadržava značajno antitumorsko djelovanje u staničnim linijama NSCLC-a in vitro i/ili modelima tumora in vivo (ksenotransplatati ili transgenski modeli) uvjetovano mutiranim EGFR izoformama poznatim da su rezistentne na reverzibilne EGFR inhibitore, erlotinib i gefitinib, kao što je T790M ili T854A.
Afebrile convulsions or seizures, Bell’s palsy, Cerebrovascular accident, Dizziness, Dream abnormality, Encephalitis*, Encephalopathy*, Guillain-Barré syndrome, Measles inclusion body encephalitis (see section 4.3), Ocular palsies, Paraesthesia, Polyneuritis, Polyneuropathy, Subacute sclerosing panencephalitis*, Syncope, Transverse myelitis, Tremor
afebrilne konvulzije ili napadaji, Bellova paraliza, cerebrovaskularni događaj, omaglica, neuobičajeni snovi, encefalitis*, encefalopatija*, Guillain-Barréov sindrom, encefalitis s inkluzijskim tjelešcima nakon cijepljenja protiv morbila (vidjeti dio 4.3), okularna paraliza, parestezija, polineuritis, polineuropatija, subakutni sklerozirajući panencefalitis*, sinkopa, transverzalni mijelitis, tremor
afety when
Lovastatin
Affect lability
labilnost afekta
Affect lability
Manje često
Affect lability Anxiety Insomnia Psychotic disorder
afektivna labilnost, anksioznost, nesanica, psihotični poremećaj
affect lability, aggression, confusional state, euphoric mood, hallucination, mania, paranoia, psychosis†, suicide attempt, suicide ideation*
emocionalna labilnost, agresija, stanje konfuzije, euforično raspoloženje, halucinacije, manija, paranoja, psihoza†, pokušaj samoubojstva, suicidalne misli
affect lability, aggression, confusional state, euphoric mood, hallucination, mania, paranoia, psychosis‡, suicide attempt, suicide ideation
emocionalna labilnost, agresija, stanje konfuzije, euforično raspoloženje, halucinacije, manija, paranoja, psihoza‡, pokušaj samoubojstva, suicidalne misli
Affect lability, agitation, libido disorder, mood altered, sleep disorder
emocionalna labilnost, agitiranost, poremećaj libida, promjene raspoloženja, poremećaj spavanja
Affected pigs often have a cough and fail to thrive.
Zahvaćene svinje često kašlju i ne napreduju.
Affected pigs often have a cough and fail to thrive.
Zaražene svinje često imaju kašalj i ne napreduju u razvoju.
Affecting other parts of the body difficulty breathing / wheezing, symptoms of allergic reaction (swelling, redness of the eye and rash of the skin), changes in your taste sensation, slowing of heart rate, difficulty sleeping, nightmare, asthma, hair loss, tiredness.
Zahvaćaju druge dijelove tijela otežano disanje/piskanje pri disanju, simptomi alergijske reakcije (oticanje, crvenilo oka i osip po koži), promjene u osjetu okusa, usporavanje srčanih otkucaja, poteškoće sa spavanjem, noćne more, astma, gubitak kose, umor.
Affecting other parts of the body headache, darker skin colour around the eye.
Zahvaćaju druge dijelove tijela glavobolja, tamnija boja kože oko oka.
Affecting other parts of the body runny nose, hair growing around the eye, dizziness, headache.
Zahvaćaju druge dijelove tijela curenje nosa, rast dlaka u području oko očiju, omaglica, glavobolja.
Affecting other parts of the body slowing of heart rate, symptoms of allergic reaction (swelling, redness of the eye and rash of the skin), asthma, shortness of breath.
Zahvaćaju druge dijelove tijela usporavanje srčanih otkucaja, simptomi alergijske reakcije (oticanje, crvenilo oka i osip po koži), astma, nedostatak zraka.
Affecting other parts of the body tiredness.
Zahvaćaju druge dijelove tijela umor.
Affecting the eye
Na razini oka
Affecting the eye cystoid macular oedema (swelling of the retina within the eye leading to worsening vision), eye swelling, blurred vision.
Zahvaćaju oko cistoidni makularni edem (oticanje mrežnice u oku što dovodi do pogoršanja vida), oticanje oka, zamućen vid.
Affecting the eye eye swelling
Zahvaćaju oko oticanje oka
Afinitor 10 mg tablets Everolimus
Afinitor 10 mg tablete everolimus
Afinitor 2.5 mg is available in packs containing 30 or 90 tablets.
Afinitor 2,5 mg dostupan je u pakiranjima od 30 ili 90 tableta.
Afinitor 2.5 mg tablets Afinitor 5 mg tablets Afinitor 10 mg tablets Everolimus
Afinitor 2,5 mg tablete Afinitor 5 mg tablete Afinitor 10 mg tablete everolimus
Afinitor 2.5 mg tablets are white to slightly yellowish, elongated tablets.
Afinitor 2,5 mg tablete su bijele do žućkaste izduljene tablete.
Afinitor 2.5 mg tablets Everolimus
Afinitor 2,5 mg tablete everolimus
Afinitor 5 mg and Afinitor 10 mg are available in packs containing 10, 30 or 90 tablets.
Afinitor 5 mg i Afinitor 10 mg dostupni su u pakiranjima od 10, 30 ili 90 tableta.
Afinitor 5 mg tablets Everolimus
Afinitor 5 mg tablete everolimus
Afinitor could harm a breast-fed baby.
Afinitor može naštetiti dojenčetu.
Afinitor could harm an unborn baby and is not recommended during pregnancy.
Afinitor može naštetiti nerođenom djetetu te se ne preporučuje tijekom trudnoće.
Afinitor is a medicine that contains the active substance everolimus.
Afinitor je lijek koji sadrži djelatnu tvar everolimus.
Afinitor is indicated for the treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.
Afinitor je indiciran u kombinaciji s eksemestanom za liječenje uznapredovalog raka dojke pozitivnog na hormonske receptore, a negativnog na HER2/neu, u žena u postmenopauzi bez simptomatske visceralne bolesti nakon recidiva ili progresije bolesti do kojih je došlo nakon uzimanja nesteroidnog inhibitora aromataze.
Afinitor is indicated for the treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.
Afinitor je indiciran za liječenje neresektabilnih ili metastatskih, dobro ili umjereno diferenciranih neuroendokrinih tumora s primarnim sijelom u gušterači, u odraslih bolesnika s progresivnom bolešću.
Afinitor is indicated for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease (see sections 4.4 and 5.1).
Afinitor je indiciran za liječenje neresektabilnih ili metastatskih, dobro diferenciranih (gradus 1 ili gradus 2) nefunkcionalnih neuroendokrinih tumora s primarnim sijelom u probavnom sustavu ili plućima, u odraslih bolesnika s progresivnom bolešću (vidjeti dijelove 4.4 i 5.1).
Afinitor is not to be used in children or adolescents (age below 18 years).
Afinitor nije namijenjen za primjenu u djece ili adolescenata (mlađi od 18 godina).
Afinitor is used in breast cancer that is ‘hormone receptor-positive’ (when the cancer cells have oestrogen receptors on their surface) and ‘HER2/neu negative’ (when the cancer cells do not contain high levels of the HER2/neu [human epidermal growth factor receptor-2] protein).
Afinitor se koristi u liječenju raka dojke koji je „pozitivan na hormonske receptore” (u slučaju kada stanice raka imaju receptore estrogena na svojoj površini) i „negativan na HER2/neu” (kada stanice raka ne sadrže visoke koncentracije proteina HER2/neu [receptor humanog epidermalnog faktora rasta-2]).
Afinitor is used to treat the following cancers:
Afinitor se koristi za liječenje sljedećih bolesti:
Afinitor may affect male fertility.
Afinitor može utjecati na plodnost muškarca.
Afinitor may elevate cholesterol and/or other blood fats. if you have had recent major surgery, or if you still have an unhealed wound following surgery.
Afinitor može povisiti razine kolesterola i/ili drugih masnoća u krvi. ako ste nedavno imali veći kirurški zahvat, ili ako imate nezacijeljenu ranu nakon kirurškog zahvata.
Afinitor may increase the risk of problems with wound healing. if you have an infection.
Afinitor može povećati rizik za probleme vezane uz cijeljenje rane. ako imate infekciju.
Afinitor must not be used in people who are hypersensitive (allergic) to other rapamycin derivatives (substances with a similar structure to everolimus) or to any of the other ingredients.
Afinitor se ne smije primjenjivati u osoba koje su preosjetljive (alergične) na derivate rapamicina (tvari koje su po strukturi slične everolimusu) ili bilo koji drugi sastojak lijeka.
Afinitor was more effective than placebo at treating patients in all studies.
Lijek Afinitor pokazao se djelotvornijim od placeba u svim ispitivanjima.
Afinitor was superior to placebo for the primary endpoint of progression-free survival, with a statistically significant 67% reduction in the risk of progression or death (see Table 7 and Figure 5).
Afinitor je bio bolji od placeba s obzirom na primarni ishoda preživljenja bez progresije bolesti, uz statistički značajno sniženje rizika za progresiju ili smrt od 67% (vidjeti Tablicu 7 i Sliku 5).
Afinitor with food and drink
Afinitor s hranom i pićem
Aflibercept acts as a soluble decoy receptor that binds to VEGF-A, with higher affinity than its native receptors, as well as the related ligands PlGF and VEGF-B.
Aflibercept djeluje kao topljivi lažni receptor koji se veže za VEGF-A većim afinitetom nego njegovi prirodni receptori, a veže se i za povezane ligande PlGH i VEGF-B.
Aflibercept acts as a soluble decoy receptor that binds VEGF-A and PlGF with higher affinity than their natural receptors, and thereby can inhibit the binding and activation of these cognate VEGF receptors.
Aflibercept djeluje kao topljivi lažni receptor koji veže VEGF-A i PlGF s većim afinitetom nego njihovi prirodni receptori pa tako može inhibirati vezanje i aktivaciju ovih srodnih VEGF receptora.
Aflibercept administration should be suspended for ≥2 grams of proteinuria/24 hours and restarted when proteinuria is <2 grams/24 hours.
Primjenu aflibercepta treba prekinuti kada je proteinurija u 24 sata ≥ 2 grama i ponovno uvesti kada proteinurija u 24 sata bude < 2 grama.
Aflibercept has been shown to be embryotoxic and teratogenic when administered intravenously to pregnant rabbits every 3 days during the organogenesis period (gestation days 6 to 18) at doses approximately 1 to 15 times the human dose of 4 mg/kg every 2 weeks.
Pokazalo se da aflibercept ima embriotoksična i teratogena svojstva kada se primjenjuje intravenski u skotnih ženki kunića svaka 3 dana tijekom razdoblja organogeneze (od 6. do 18. dana gestacije) pri dozama od približno 1 do 15 puta većima od doze od 4 mg/kg svaka 2 tjedna primijenjene u ljudi.
Aflibercept impaired wound healing in animal models (see section 5.3).
Aflibercept je u životinjskim modelima otežao zacjeljivanje rana (vidjeti dio 5.3).
Aflibercept is a dimeric glycoprotein with a protein molecular weight of 97 kilodaltons (kDa) and contains glycosylation, constituting an additional 15% of the total molecular mass, resulting in a total molecular weight of
Aflibercept je dimerički glikoprotein proteinske molekularne težine 97 kilodaltona (kDa), a sadrži glikozilaciju koja čini dodatnih 15% ukupne molekularne mase, pa ukupna molekularna težina iznosi 115 kDa.
Aflibercept is an engineered protein that has been designed to attach to and block the effects of a substance called vascular endothelial growth factor A (VEGF-A).
Aflibercept je industrijski proizvedena bjelančevina čija je namjena vezanje na i blokiranje djelovanja tvari poznate pod nazivom vaskularni endotelialni čimbenika rasta A (VEGF-A).
Aflibercept treatment should be discontinued in patients who experience an ATE (see section 4.2).
U bolesnika u kojih dođe do pojave arterijskog tromboembolijskog događaja treba obustaviti liječenje afliberceptom (vidjeti dio 4.2).
Aflibercept treatment should be discontinued in patients who experience GI perforation (see section 4.2).
U bolesnika u kojih dođe do gastrointestinalne perforacije treba obustaviti liječenje afliberceptom (vidjeti dio 4.2).
Aflibercept, also known as VEGF TRAP in the scientific literature, is a recombinant fusion protein consisting of VEGF-binding portions from the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion of the human IgG1.
Aflibercept, u znanstvenoj literaturi poznat i kao VEGF TRAP, je rekombinantni fuzijski protein koji se sastoji od dijelova izvanstaničnih domena humanih VEGF receptora 1 i 2 spojenih za dio Fc humanog IgG1 koji na sebe vezuju VEGF.
Aflunov contains less than 1 mmol sodium (23 mg) and less than 1 mmol of potassium (39 mg) per 0.5 ml dose, i.e. essentially sodium- and potassium-free.
Aflunov sadrži manje od 1 mmol natrija (23 mg) i manje od 1 mmol kalija (39 mg) po dozi od 0,5 ml, tj. u osnovi je bez natrija i kalija.
AFLUNOV contains sodium and potassium
AFLUNOV sadrži natrij i kalij
AFLUNOV has been evaluated in healthy adults (18-60 years of age) and healthy elderly (over 60 years of age) following a 1, 22 day primary vaccination schedule, and booster vaccination (see sections 4.8 and 5.1).
AFLUNOV je procijenjen u zdravih odraslih osoba (u dobi od 18 do 60 godina) i zdravih starijih osoba (u dobi od 60 godina naviše) slijedeći raspored primarnog cijepljenja po principu na dan 1, pa 22 dana te booster cijepljenje (vidjeti dijelove 4.8 i 5.1).
AFLUNOV injection H5N1 influenza vaccine IM
AFLUNOV injekcija cjepivo protiv influence H5N1 i.m.
AFLUNOV is a vaccine for use in adults (from 18 to 60 years old). and elderly (over 60 years old).
AFLUNOV je cjepivo za primjenu u odraslih osoba (u dobi od 18 do 60 godina) i starijih osoba (više od 60 godina).
AFLUNOV may contain trace residues of egg and chicken proteins, ovalbumin, kanamycin and neomycin sulphate, barium sulphate, formaldehyde, cetyltrimethylammonium bromide (CTAB) and which are used during the manufacturing process (see section 4.3).
AFLUNOV može sadržavati ostatne tragove jaja i pilećih proteina, ovalbumina, kanamicina i neomicin sulfata, barijeva sulfata, formaldehida i cetiltrimetilamonijeva bromida (CTAB) koji se upotrebljavaju tijekom postupka proizvodnje (vidjeti dio 4.3).
AFLUNOV, containing HA from A/Vietnam/1194/2004 (homologous to the challenge strain) and an AFLUNOV-like H5N1 vaccine, containing hemagglutinin from the A/turkey/Turkey/1/2005-like (heterologous to the challenge strain) were tested.
Testirano je AFLUNOV koje je sadržavalo antigen HA iz virusa A/Vietnam/1194/2004 (homologan ispitivanom soju pokusa) i H5N1 cjepivo slično cjepivu AFLUNOV koje je sadržavalo hemaglutinin iz virusa sličnog A/turkey/Turkey/1/2005 (heterologan ispitivanom soju).
Afoxolaner
Afoksolaner
Afoxolaner / milbemycin oxime
Afoksolaner / milbemicin oksim
afoxolaner / milbemycin oxime Tablets
afoxolaner / milbemycin oxime Tablete
Afoxolaner 11.3 mg Afoxolaner 28.3 mg Afoxolaner 68 mg Afoxolaner 136 mg
Afoxolaner 11,3 mg Afoxolaner 28,3 mg Afoxolaner 68 mg Afoxolaner 136 mg
Afoxolaner acts as an antagonist at ligand-gated chloride channels, in particular those gated by the neurotransmitter gamma-aminobutyric acid (GABA).
Afoksolaner djeluje kao antagonist na ligandom regulirane kloridne kanale, osobito one kojim upravlja neurotransmiter gama- aminomaslačna kiselina (GABA).
Afoxolaner had high systemic absorption.
Afoksolaner je imao visoku sustavnu apsorpciju.
Afoxolaner in the dog is metabolized to more hydrophilic compounds and then eliminated.
Afoksolaner u psa se metabolizira u više hidrofilnih spojeva, a zatim eliminira.
Afoxolaner is an insecticide and acaricide of the isoxazoline family.
Afoksolaner je insekticid i akaricid koji pripada skupini izoksazolina.
Afoxolaner kills fleas before they can lay eggs and so helps to reduce contamination of the dogs’ environment.
Afoksolaner ubija buhe prije nego što izlegnu jajašca, te tako pomaže pri smanjivanju kontaminacije okruženja psa
Afoxolaner kills fleas before they can lay eggs and so helps to reduce contamination of the dogs’ environment.
Afoksolaner ubija buhe prije nego što one uspiju izleći jaja, te tako pomaže u smanjenju kontaminacije okruženja pasa.
Africa, Latin America
Afrika, Latinska Amerika
African-America/African Heritage/Other
afroameričko/afričko/drugo podrijetlo
African-American patients
Afroamerički bolesnici
African-American/African Heritage/Other
Afroamerikanci/afričko podrijetlo/ostalo
After
Nakon
After
Nakon davanja
After 1 dose of 0.5 ml
nakon 1 doze od 0,5 ml
After 1 or 2 doses of 106.7 TCID50 vaccine, haemagglutination inhibition (HAI) and IgA seroresponses were each detected in 10% subjects, and nasal wash IgA responses were detected in 24% subjects.
Nakon 1 ili 2 doze cjepiva od 106,7 TCID50, u po 10% ispitanika zabilježeni su i inhibicija hemaglutinacije (engl. haemagglutination inhibition, HAI) i IgA serološki odgovori, dok je uzimanjem nazalnog ispirka zabilježen IgA odgovor u 24% ispitanika.
After 1 or 2 doses of 107.5 TCID50 vaccine, HAI and IgA seroresponses were each detected in 10% and 52% of subjects and nasal IgA responses were detected in 19% of subjects.
Nakon 1 doze cjepiva od 107,5 TCID50, HAI i IgA serološki odgovori zabilježeni su u 10% ispitanika dok je nakon 2 doze zabilježen u 52% ispitanika, a nazalni IgA odgovor je zabilježen u 19% ispitanika.
After 1 year of treatment, around 66% of patients receiving Imbruvica were still alive with their disease not having progressed compared with around 6% of patients receiving ofatumumab.
Nakon jedne godine liječenja, otprilike 66 % bolesnika liječenih lijekom Imbruvica bilo je još uvijek živo, pri čemu nije došlo do razvoja njihove bolesti, u usporedbi s otprilike 6 % bolesnika koji su primali ofatumumab.
After 10 seconds pull the pen straight out to remove the needle from the injection site.
Nakon 10 sekundi ravno izvucite brizgalicu kako biste uklonili
After 10 seconds, keep the dose setting knob pressed down, and take the needle out of your skin.
Nakon 10 sekundi držite tipku pritisnutom te izvucite iglu iz kože.
After 10 years of follow-up in GEICAM 9805 study, , acute leukaemia occurred in 1 of 532 (0.2%) patients in TAC arm .
Nakon 10 godina pračenja GEICAM 9805 u studiji akutna leukemija pojavila se u 1 od 532 bolesnika (0,2%) u TAC skupini.
After 10 years of follow-up in GEICAM 9805 study, , acute leukaemia occurred in 1 of 532 (0.2%) patients in TAC arm.
Nakon 10 godina praćenja u GEICAM 9805 studiji, akutna leukemija pojavila se u 1 od 532 bolesnika (0,2%) u TAC skupini.
After 10 years of follow-up in GEICAM 9805 study, , acute leukaemia occurred in 1 of 532 (0.2%) patients in TAC arm.
Nakon 10 godina praćenja u GEICAM 9805 studiji, akutna leukemija pojavila se u 1 od 532 bolesnika (0,2%)u TAC skupini.
After 10 years of follow-up in GEICAM 9805 study, acute leukaemia occurred in 1 of 532 (0.2%) patients in TAC arm.
Nakon 10 godina praćenja u GEICAM 9805 studiji akutna leukemija pojavila se u 1 od 532 bolesnika (0,2%) u TAC skupini.
After 10 years of follow-up in GEICAM 9805 study, acute leukaemia occurred in 1 of 532 (0.2%) patients in TAC arm.
Nakon 10 godina praćenja u GEICAM 9805 studiji, akutna leukemija pojavila se u 1 od 532 bolesnika (0,2%) u TAC skupini.
After 10 years of follow-up in GEICAM 9805 study, acute leukaemia occurred in 1 of 532 (0.2%) patients. in TAC arm.
Nakon 10 godina praćenja u GEICAM 9805 studiji akutna leukemija pojavila se u 1 od 532 bolesnika (0,2%) u TAC skupini.
After 10 years of follow-up in GEICAM 9805 study,, acute leukaemia occurred in 1 of 532 (0.2%) patients in TAC arm .
Nakon 10 godina praćenja u GEICAM 9805 studiji akutna leukemija pojavila se u 1 od 532 bolesnika (0,2%) u TAC skupini.
After 12 months (month 36), 856 patients (93%) were still enrolled.
12 mjeseci (36. mjesec), 856 bolesnika (93%) bilo je još uvijek uključeno.
After 12 months of treatment, the percentage of patients meeting the primary composite endpoint (composed of all four components mentioned in Table 4) was 84.8% [95% confidence interval 76.2% - 91.3%] for the Cerdelga group compared to 93.6% [95% confidence interval 82.5% - 98.7 %] for the Cerezyme group.
Nakon 12 mjeseci liječenja, postotak bolesnika koji su postigli primarni kompozitni ishod (koji se sastoji od sve četiri komponente navedene u Tablici 4) iznosio je 84,8% [95% interval pouzdanosti 76,2% - 91,3%] za skupinu liječenu lijekom Cerdelga u usporedbi s 93,6% [95% interval pouzdanosti 82,5% - 98,7 %] za skupinu liječenu lijekom Cerezyme.
After 12 months this evaluation should include suspension of Protopic treatment in paediatric patients (see section 4.2).
Nakon 12 mjeseci, ti pregledi trebaju uključiti obustavu liječenja Protopicom u pedijatrijskih bolesnika (vidjeti dio 4.2).
After 12 months this evaluation should include suspension of Protopic treatment in paediatric patients (see section 4.2).
Nakon 12 mjeseci, ti pregledi trebaju uključiti privremenu obustavu liječenja Protopicom u pedijatrijskih bolesnika (vidjeti dio 4.2).
After 12 months treatment with bimatoprost eye drops alone, the incidence was 1.5% and did not increase following 3 years treatment.
Nakon 12 mjeseci liječenja kapima za oko koje sadrže samo bimatoprost, incidencija je bila 1,5% i nije se povećavala tijekom daljnje 3 godine liječenja.
After 12 to 18 months of maintenance therapy, Replagal improved renal function as measured by inulin based glomerular filtration rate by 8.7 ± 3.7 ml/min. (p=0.030).
Nakon 12 do 18 mjeseci terapije održavanja Replagal je poboljšao funkciju bubrega mjereno brzinom glomerularne filtracije inulina za 8,7 ± 3,7 ml/min (p=0,030).
After 12 to 18 months treatment a reduction of 50 – 80% was observed in plasma and urine sediment.
Nakon 12 - 18 mjeseci liječenja opaženo je smanjenje u plazmi i sedimentu urina za 50 do 80%.